Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05251259 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 670
- Enrollment target
NCT05251259 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 670 participants.
The verdict
NCT05251259, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 670 participants
- Enrollment target
Study Summary
This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
Interventions
- DRUG Placebo
- DRUG Atuliflapon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 670 participants |
| Start Date | 2022-01-27 |
| Est. Completion | 2026-01-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05251259
The ClinicalTrials.gov registry entry for NCT05251259 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 670 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05251259 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05251259 about?
NCT05251259 is a clinical study titled "Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-Severe Uncontrolled Asthma". This is a randomised, placebo-controlled, double-blind study to assess the efficacy and safety of Atuliflapon administered once daily over a 12-week treatment period to adult participants with moderate to severe uncontrolled asthma.
What is the current status of trial NCT05251259?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 670 participants. The study started on 2022-01-27. Estimated completion is 2026-01-07.
What interventions are being tested in trial NCT05251259?
The interventions under investigation include: Placebo (DRUG), Atuliflapon (DRUG).
Who is sponsoring clinical trial NCT05251259?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.